Skip to main content

Featured

Canadians Gain More Room to Save with 2025 TFSA Limit

  The Tax-Free Savings Account (TFSA) contribution limit for 2025 has been set at $7,000 , giving Canadians another opportunity to grow their investments tax-free. Since its launch in 2009, the TFSA has become one of the most popular savings tools in the country, offering flexibility and tax advantages that appeal to both short-term savers and long-term investors. For those who have never contributed to a TFSA and were eligible since the beginning, the total cumulative contribution room now stands at $102,000 . This allows Canadians to deposit a significant amount into their accounts without worrying about taxes on investment gains, dividends, or withdrawals. One of the TFSA’s biggest advantages is that withdrawals are tax-free and the amount withdrawn is added back to your contribution room the following year . This makes it ideal for saving toward major purchases, retirement, or even emergency funds. Unlike RRSPs, contributions are not tax-deductible, but the growth inside the...
Post a Comment
Read more

article

Labels

Revolutionary Gene Therapy Restores Hearing in Deaf Toddler

 

In a remarkable medical breakthrough, an 18-month-old toddler named Opal Sandy has regained her hearing thanks to a pioneering gene therapy trial. Born deaf due to a rare genetic condition affecting the OTOF gene, which is responsible for producing a protein essential for hearing, Opal’s prospects for natural hearing were bleak. However, the innovative treatment at Cambridge University Hospitals in England has opened up a world of sound for her.

The procedure involved the infusion of a working copy of the OTOF gene into Opal’s right ear, a process that took a mere 16 minutes. Remarkably, within weeks, Opal began responding to loud noises, and after 24 weeks, she could hear whispers, indicating a near-normal level of hearing restoration.

Opal’s case is part of the Chord trial, which is recruiting more children from the UK, Spain, and the US to undergo similar treatment. The trial is being closely monitored, with participants followed up for five years to assess the long-term efficacy and safety of the therapy.

The success of this gene therapy is a beacon of hope for many suffering from genetic deafness, signaling the dawn of a new era in medical science where conditions once thought incurable are now within the realm of treatment. Opal’s story is not just a personal victory; it’s a milestone in genetic medicine, showcasing the incredible potential of gene therapy to change lives.

Labels:

Comments

Post a Comment